HK1213582A1 - 能夠特異性地識別轉鐵蛋白受體的抗體 - Google Patents

能夠特異性地識別轉鐵蛋白受體的抗體

Info

Publication number
HK1213582A1
HK1213582A1 HK16101588.8A HK16101588A HK1213582A1 HK 1213582 A1 HK1213582 A1 HK 1213582A1 HK 16101588 A HK16101588 A HK 16101588A HK 1213582 A1 HK1213582 A1 HK 1213582A1
Authority
HK
Hong Kong
Prior art keywords
transferrin receptor
antibody capable
specifically recognizing
recognizing transferrin
specifically
Prior art date
Application number
HK16101588.8A
Other languages
English (en)
Inventor
Yoshikazu Kurosawa
Kazuhiro Morishita
Lilin Zhang
Gene Kurosawa
Katsuyuki Mitomo
Yukio Sudo
Fumiko Nomura
Yoshinori Ukai
Original Assignee
Univ Miyazaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miyazaki filed Critical Univ Miyazaki
Publication of HK1213582A1 publication Critical patent/HK1213582A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16101588.8A 2012-11-08 2016-02-14 能夠特異性地識別轉鐵蛋白受體的抗體 HK1213582A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012246215 2012-11-08
PCT/JP2013/080249 WO2014073641A1 (ja) 2012-11-08 2013-11-08 トランスフェリン受容体を特異的に認識できる抗体

Publications (1)

Publication Number Publication Date
HK1213582A1 true HK1213582A1 (zh) 2016-07-08

Family

ID=50684735

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101588.8A HK1213582A1 (zh) 2012-11-08 2016-02-14 能夠特異性地識別轉鐵蛋白受體的抗體

Country Status (18)

Country Link
US (1) US9593165B2 (zh)
EP (1) EP2918603B1 (zh)
JP (1) JP6212497B2 (zh)
CN (1) CN104797600A (zh)
AU (1) AU2013342432A1 (zh)
CA (1) CA2893794C (zh)
CY (1) CY1121158T1 (zh)
DK (1) DK2918603T3 (zh)
ES (1) ES2689782T3 (zh)
HK (1) HK1213582A1 (zh)
HR (1) HRP20181453T1 (zh)
HU (1) HUE039920T2 (zh)
LT (1) LT2918603T (zh)
PL (1) PL2918603T3 (zh)
PT (1) PT2918603T (zh)
RS (1) RS57696B1 (zh)
SI (1) SI2918603T1 (zh)
WO (1) WO2014073641A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
LT3325509T (lt) * 2015-07-22 2021-06-10 Inatherys Anti-tfr antikūnai ir jų panaudojimas proliferacinių ir uždegiminių sutrikimų gydymui
AU2019384781A1 (en) * 2018-11-20 2021-06-10 Perseus Proteomics Inc. Agent for inhibiting iron uptake into cells
CN114364699B (zh) * 2019-09-04 2024-03-29 株式会社英仙蛋白质科学 红细胞增多症治疗药
EP4031696A4 (en) * 2019-09-20 2023-02-22 Navi Bio-Therapeutics, Inc. PERSONALIZED CANCER IMMUNOTHERAPY
EP4066858A4 (en) * 2019-11-27 2023-12-27 Perseus Proteomics Inc. THERAPEUTIC AGENT FOR CARCINOMATOUS PERITONITIS
US20240288453A1 (en) 2020-10-08 2024-08-29 National University Corporation Tokai National Higher Education And Research System Method for determining medicinal effect or sensitivity of anti-transferrin receptor antibody
EP4393509A1 (en) 2021-08-26 2024-07-03 Perseus Proteomics Inc. Reactive oxygen species (ros) production promoter
MX2024002753A (es) 2021-09-01 2024-05-20 Biogen Ma Inc Anticuerpos anti receptor de transferrina y usos de los mismos.
WO2023204181A1 (ja) * 2022-04-19 2023-10-26 学校法人東海大学 Ｎｋ細胞腫瘍の治療剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5589211A (en) 1985-06-24 1996-12-31 Cox; James P. Methods for processing poultry shell eggs
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2081368A1 (en) 1990-03-27 1991-09-28 Ian S. Trowbridge Method for inhibiting cell growth and compositions useful therefor
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
DE69331089T2 (de) 1992-02-18 2002-07-18 Otsuka Kagaku K.K., Osaka Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP4942644B2 (ja) 2005-02-28 2012-05-30 株式会社抗体研究所 抗ＩｇＳＦ４抗体及びその利用
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
CN101245107B (zh) * 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
WO2013031619A1 (ja) * 2011-08-26 2013-03-07 学校法人藤田学園 抗ヒトトランスフェリン受容体抗体を含む画像用腫瘍診断剤
JP5939855B2 (ja) * 2012-03-23 2016-06-22 国立大学法人 宮崎大学 トランスフェリン受容体抗体

Also Published As

Publication number Publication date
CY1121158T1 (el) 2020-05-29
EP2918603A4 (en) 2016-06-29
US20150291697A1 (en) 2015-10-15
ES2689782T3 (es) 2018-11-15
RS57696B1 (sr) 2018-12-31
WO2014073641A1 (ja) 2014-05-15
JPWO2014073641A1 (ja) 2016-09-08
US9593165B2 (en) 2017-03-14
SI2918603T1 (sl) 2018-12-31
HUE039920T2 (hu) 2019-02-28
PL2918603T3 (pl) 2019-01-31
DK2918603T3 (en) 2018-10-15
JP6212497B2 (ja) 2017-10-11
CA2893794C (en) 2021-11-09
CN104797600A (zh) 2015-07-22
CA2893794A1 (en) 2014-05-15
EP2918603A1 (en) 2015-09-16
HRP20181453T1 (hr) 2018-12-14
LT2918603T (lt) 2018-10-25
EP2918603B1 (en) 2018-08-29
PT2918603T (pt) 2018-10-30
AU2013342432A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
HRP20181453T1 (hr) Protutijelo koje može specifično prepoznavati receptor transferina
HK1201296A1 (zh) 抗體的 區變異體
HK1193833A1 (zh) 能夠特異性識別轉鐵蛋白受體的抗體
ZA201502213B (en) Antibodies recognizing alpha-synuclein
HK1204571A1 (zh) 蛋白酶調節的抗體
HK1210192A1 (zh) 抗體
AP2014008102A0 (en) Anti-FcRn antibodies
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
EP2832855A4 (en) NEW ANTI-SIGLEC ANTIBODY-15
EP2844290A4 (en) NOVEL ANTIBODIES
ZA201407316B (en) Anti-fgfr2 antibody
EP2861623A4 (en) NEW SPECIFIC CLEC14A ANTIBODY AND USES THEREOF
EP2826790A4 (en) GREMLIN-1 ANTIBODY
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
HK1210186A1 (zh) 抗體
GB201220242D0 (en) Antibody
HK1202454A1 (zh) 抗- -選擇蛋白抗體製劑
HK1199040A1 (zh) 抗體用途
EP2804876A4 (en) NEW ANTIBODIES
EP2848633A4 (en) ANTI-CXADR ANTIBODY
HK1210182A1 (zh) 抗前動力蛋白受體 抗體及其使用
HK1201845A1 (zh) 能夠特異性識別天冬酰胺合成酶的單克隆抗體
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
GB201209584D0 (en) Modified antibodies